An Antiviral Mechanism of Nitric Oxide Inhibition of a Viral Protease by Saura, Marta et al.
Immunity, Vol. 10, 21±28, January, 1999, Copyright 1999 by Cell Press
An Antiviral Mechanism of Nitric Oxide:
Inhibition of a Viral Protease
Exogenous NO inhibits replication of Coxsackievirus
and poliovirus in vitro, reducing viral RNA and protein
synthesis. Thus, iNOS and NO are important compo-
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Institut fuÈ r Molekulare Virologie replication, we first determined that NO inhibits CVB3
OberschleiaÂ heim D85758 replication by blocking a step early in the viral life cycle.
Germany We infected HeLa cells with CVB3 and then at various
³Department of Biochemistry times treated the infected cells with NO donors or con-
Brandeis University trol compounds; after 10 hr, we measured the amount
Waltham, Massachusetts 02254 of CVB3 produced during one viral life cycle. The NO
donor S-nitroso-acetyl-penicillamine (SNAP) reduces
the amount of CVB3 produced by infected HeLa cells,
and the maximum effect of SNAP occurs when the NOSummary
donor is added 1±2 hr after infection (Figure 1). In con-
trast, the control compound acetyl-penicillamine (AP)Although nitric oxide (NO) kills or inhibits the replica-
has no effect. When SNAP is added to HeLa cells, mosttion of a variety of intracellular pathogens, the antimi-
of the NO is released within 2 hr (data not shown). Sincecrobial mechanisms of NO are unknown. Here, we iden-
the life cycle of CVB3 lasts approximately 8 hr, thesetify a viral protease as a target of NO. The life cycle
data suggest that NO inhibits an early step in the lifeof many viruses depends upon viral proteases that
cycle of CVB3.cleave viral polyproteins into individual polypeptides.
Coxsackievirus, a member of the Picornaviridae, is aNO inactivates the Coxsackievirus protease 3C, an
nonenveloped virus with a single-stranded RNA ge-enzyme necessary for the replication of Coxsackie-
nome, whose life cycle includes virion attachment to thevirus. NO S-nitrosylates the cysteine residue in the
host cell, penetration, translation of the viral RNA intoactive site of protease 3C, inhibiting protease activity
a polyprotein, autocleavage of the polyprotein by viraland interrupting the viral life cycle. Substituting a ser-
proteases into viral polypeptides, replication of the viraline residue for the active site cysteine renders prote-
genome, assembly of the virion, and exit from the cell.ase 3C resistant to NO inhibition. Since cysteine pro-
Since protease activity is a critical step early in the lifeteases are critical for virulence or replication of many
cycle of Coxsackievirus, we hypothesized that NO inhib-viruses, bacteria, and parasites, S-nitrosylation of
its CVB3 proteases.pathogen cysteine proteases may be a general mecha-
nism of antimicrobial host defenses.
Exogenous NO Inhibits Protease Processing
of an Endogenous Viral PolyproteinIntroduction
In order to examine the effect of NO upon viral protease
processing of viral proteins, we added the NO donorNitric oxide (NO) is an antiviral effector of the immune
system (Mannick, 1995; Fang, 1997; MacMicking et al., SNAP or its control AP to infected HeLa cells; cell lysates
were harvested at various times after infection, fraction-1997; Reiss and Komatsu, 1998). Viral infection can in-
duce expression of the inducible nitric oxide synthase ated by SDS-PAGE, and analyzed by immunoblotting
for viral polypeptides. NO inhibits proteolysis of the viral(iNOS) in cells and in animals. NO inhibits the replication
of a variety of viruses (Croen, 1993; Karupiah et al., 1993; protein precursor 2ABC, delaying and reducing the
amount of the cleavage products 2BC and 2C detectedBi and Reiss, 1995; Bukrinsky et al., 1995; Hooper et al.,
1995; Akaike et al., 1996; Komatsu et al., 1996; Tucker by immunoblotting (Figure 2A). Since 3Cpro is responsible
for cleavage of 2ABC, one interpretation of these dataet al., 1996). We and others have previously shown that
NO inhibits the replication of Coxsackievirus and other is that exogenous NO inhibits the proteolysis of the viral
polypeptide 2BC.Picornaviruses (Komatsu et al., 1996; Lowenstein et al.,
1996; Mikami et al., 1996; Flynn et al., 1997; Haddad et
al., 1997; Zaragoza et al., 1997, 1998). Coxsackievirus Endogenous NO Inhibits Protease Processing
B3 (CVB3) infection induces iNOS expression in macro- of an Endogenous Viral Polyprotein
phages in mice, and CVB3 replicates more rapidly to To answer the question of whether or not endogenous
higher titers and causes more tissue damage in mice NO produced by iNOS would also interfere with viral
lacking iNOS, compared to infections of wild-type mice. proteolytic processing, we added macrophages that
had been induced to express iNOS to infected cells.
First, HeLa cells were infected with CVB3, and then cell§ To whom correspondence should be addressed (e-mail: clowenst@
welchlink.welch.jhu.edu). culture inserts were added that contained RAW 264.7
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Figure 1. The NO Donor SNAP Inhibits CVB3 Replication
HeLa cells were infected with CVB3 at a multiplicity of infection of
10. SNAP (200 mM) was added at various times after infection as
indicated. The amount of CVB3 after 10 hr of infection was measured
by the plaque assay. To one set of infected cells (C), 200 mM AP
was added 1 hr after infection. To another set of cells (-1), SNAP
was added 1 hr before infection. n 5 3 6 SD.
macrophages, activated or not with lipopolysaccharide
and interferon-g. The macrophages were separated
from the infected HeLa cells by a 0.4 mM pore size
membrane, which would allow the passage of NO from
macrophages to infected cells. The NOS inhibitor nitro-
arginine-methyl-ester (NAME) was added to some co-
cultures of infected HeLa cells and activated macro-
phages, in order to confirm that any antiviral effect of
activated macrophages was a result of NO, and not
Figure 2. Figure 2. NO Inhibits Proteolysis of CVB3 Polypeptide 2BCsome other mechanism. Cells were harvested 5 hr after in Infected Cells
infection, and the cleavage of the viral polyprotein 2ABC
(A) Exogenous NO donor SNAP inhibits proteolysis of CVB3 poly-
was measured by immunoblotting as above. peptide. HeLa cells were infected with CVB3 at a multiplicity of
Activated macrophages block proteolytic processing infection of 10. After 1 hr, 200 mM of SNAP (1) or AP (-) was added,
of the CVB3 polyprotein 2ABC, resulting in a decrease and after 3.5 hr guanidine was added to inhibit new viral RNA synthe-
sis. HeLa cells were harvested at various times indicated after guani-in the amount of 2BC and 2C (Figure 2B). Infected HeLa
dine treatment. Cell lysates were fractionated by SDS-PAGE andcells alone (lane 2) contain three prominent polypeptides
immunoblotted with an antibody to CVB3 polypeptide 2C. Theserecognized by the antibody to 2C (as well as another
experiments were repeated twice with similar results.
band also found in noninfected cells [lane 1]). These (B) Endogenous NO from activated macrophages inhibits proteoly-
three polypeptides are 2ABC and its two proteolytic sis of CVB3 polypeptide. HeLa cells were infected with CVB3 at a
products 2BC and 2C. Resting macrophages (lane 3) do multiplicity of infection of 10. After 1 hr, plastic inserts containing
resting (R) or LPS/IFN-stimulated (S) macrophages were added tonot affect the intensity of the three viral polypeptides.
the wells containing infected HeLa cells. Some cultures were alsoHowever, macrophages activated by lipopolysaccha-
treated with the NOS inhibitor NAME (0±10 mM). Cells were har-ride (LPS) and interferon-g (IFNg) (lane 4) release a solu-
vested 5 hr after infection and cell lysates analyzed for CVB3 poly-
ble mediator that diffuses across the 4 mM pores and peptide 2C as above. This experiment was repeated five times with
inhibits the processing of 2ABC into 2BC and 2C. This similar results.
soluble mediator may be NO, since increasing concen- (C) LPS or IFN do not directly affect CVB3 replication. HeLa cells
were infected with CVB3 at a multiplicity of infection of 10. After 1trations of the NOS inhibitor NAME are associated with
hr, LPS or IFN or media alone was added to the wells containingdecreasing amounts of NO and also with increasing pro-
infected HeLa cells. Some cultures were also treated with the NOSteolytic processing of the viral polypeptide (lanes 5±7).
inhibitor NAME (0±10 mM). Cells were harvested 5 hr after infection
(LPS or IFN alone have no effect upon viral replication and cell lysates analyzed for CVB3 polypeptide 2C as above.
in HeLa cells [Figure 2C].) Thus, NO synthesized by acti-
vated macrophages can diffuse into infected cells and
boundary between the structural proteins and the non-inhibit the viral proteases that process the viral poly-
structural proteins, VP1 and 2A, producing two polypro-proteins.
teins. The protease 3Cpro is thought to cleave the re-Since exogenous and endogenous NO inhibit proteo-
sulting polyproteins into ten viral polypeptides, includinglytic processing of Coxsackievirus polyproteins, we
the cleavage of 2BC into 2B and 2C (Ivanoff et al., 1986;therefore focused our attention on the effect of NO upon
Hammerle et al., 1991; Miyashita et al., 1993). The prote-Coxsackievirus proteases.
ase 3Cpro is a critical component of the Picornavirus life
cycle: mutation of any of the three amino acids in the
active site of 3Cpro inactivates the protease and abol-NO Inhibits CVB3 Protease Activity
Picornaviruses encode two cysteine proteases, 2Apro ishes viral replication (Ivanoff et al., 1986; Hammerle et
al., 1991; Miyashita et al., 1993). One of the residues ofand 3Cpro (KraÈ usslich and Wimmer, 1988; Hellen et al.,
1989; Palmberg, 1990; Dougherty and Semler, 1993). the catalytic site of 3Cpro is cysteine at amino acid posi-
tion 147, and since NO can nitrosylate cysteine residuesThe protease 2Apro cleaves the viral polyprotein at the
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of 3C included in the fusion protein consists of the first
140 amino acids of 3C. It lacks the Cys147 of the active
site and is thus incapable of protease activity.)
To test the activity of recombinant protease, purified
3Cpro was incubated with the protease substrate GST-
3B-3CT and the reaction mixture analyzed by immu-
noblotting with an antibody to GST. Purified 3Cpro is
capable of cleaving the polyprotein GST-3B-3CT, as de-
tected by immunoblotting (Figure 3B, immunoblot lanes
1 and 2).
In order to measure the susceptibility of 3Cpro to NO,
we added a variety of NO donors or their controls to
3Cpro and a protease substrate. The NO donor SNAP
inhibits the proteolytic activity of 3Cpro in a dose-depen-
dent manner, while its control acetyl-penicillamine (AP),
which has no nitroso group, has no effect (Figure 3B).
DTT, an agent capable of reducing the nitrosylation of
cysteine residues, reverses the NO inhibition of 3Cpro.
Another NO donor, spermine NONOate, also inhibits
3Cpro cleavage of GST-3B-3CT. DTT also reverses this
effect (Figure 3C).
To confirm these results, we used luciferase as an-
other protease substrate (Holzman and Baldwin, 1980;
Gorbalenya and Svitkin, 1983; Thompson et al., 1997).
Firefly luciferase serves as a 3Cpro substrate because it
contains the 3Cpro motif AXXQG. Cleavage of luciferase
was measured by monitoring luciferase activity. 3Cpro
cleaves luciferase in a dose- and time-dependent man-
ner (Figures 4A and 4B). The NO donors SNAP or sperm-
ine NONOate but not their corresponding control drugs
inhibit 3Cpro activity, and these inhibitions are reversed
by DTT (Figure 4C). It was previously shown that the
Figure 3. NO Inhibits Cleavage of a Viral Target by Purified 3Cpro nonphysiological reagents iodoacetamide and N-ethyl-
(A) 3Cpro was expressed in bacteria and purified. Bacterial lysates maleimide can inhibit 3Cpro (Gorbalenya and Svitkin,
were subjected to SDS-PAGE: lane 1, noninduced bacteria; lane 1983; Orr et al., 1989). Thus, NO inhibits the activity of
2, bacteria induced with IPTG; lane 3, high-speed supernatant of 3Cpro.
induced bacteria; lane 4, flow-through from a Ni1 column; lanes 5±9,
sequential column washes with 10 mM imidazole; and lanes 10±13,
fractions from a Ni1 column eluted with 500 mM imidazole.
NO Nitrosylates the CVB3 Protease Active(B) The purified fusion protein GST-3B-3CT, which contains an au-
thentic 3Cpro cleavage site, was incubated with buffer, purified 3Cpro, Site Cysteine
or 3Cpro with the control compound AP, or the NO donor SNAP, or 3Cpro has only one cysteine, namely Cys147 in the active
SNAP and DTT. The reaction mixture was analyzed by immunoblot site. To determine whether or not NO nitrosylates this
with an antibody to GST and quantitated by densitometry. n 5 3 6
cysteine, we first measured the effect of NO donorsSD, and * p , 0.05.
upon its thiol group with the Ellman assay (Ellman, 1959;(C) The cleavage experiment was then repeated using spermine
Zhang et al., 1996). Purified 3Cpro was incubated withNONOate (SP-NO) as an NO donor or its control compound spermine
(SP). n 5 3 6 SD, and * p , 0.05. NO donors for 1 hr and then dialyzed. 5,59- Dithiobis
(2-nitrobenzoic acid) was added, the increase of ab-
sorbance at 412 nm was measured, and the concentra-(Stamler et al., 1992a, 1992b; Stamler, 1994), we hypoth-
tion of thiols was calculated from the molar extinctionesized that NO inhibits the CVB3 3Cpro.
coefficient of the nitrothiobenzoate ion. NO donors butWe therefore prepared pure 3Cpro and various prote-
not their corresponding control compounds eliminatease substrates. We subcloned the cDNA encoding 3Cpro
the sulfhydryl group from purified 3Cpro over time (Fig-into a bacterial expression vector, expressed a fusion
ure 5A).protein consisting of 3Cpro tagged with His6 in bacteria,
We next measured the effect of NO donors upon theand then purified 3Cpro (Figure 3A) (Ghosh and Low-
formation of a nitroso-thiol group by the Saville assayenstein, 1996). To prepare an authentic protease sub-
(Saville, 1958; Zhang et al., 1996). Purified 3Cpro wasstrate, we subcloned, expressed, and purified a fusion
incubated with various NO donors or their controls, andpolypeptide, consisting of glutathione-S-transferase, the
excess NO donors and nitrite were removed from theentire CVB3 3B polypeptide, and the amino acid residues
sample with Sephadex G-25 column chromatography.1±140 of 3C; we refer to this fusion protein as GST-
3Cpro was then incubated with HgCl2 and the amount of3B-3CT. This fusion protein contains an authentic 3Cpro
nitrite was measured in the Griess reaction (Stamler etcleavage site between 3B and 3C, consisting of the 3Cpro
al., 1992a). For every 1 mole of 3Cpro added to the reac-recognition motif AXXQG (where Q is the P1 residue)
tion, approximately 1 mole of nitrite is detected (Figure(KraÈ usslich and Wimmer, 1988; Hellen et al., 1989; Law-
son and Semler, 1990; Palmberg, 1990). (The fragment 5B). These data suggest that NO nitrosylates 3Cpro on a
Immunity
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Figure 5. NO Eliminates a Sulfhydryl Group from 3Cpro and Nitrosy-
lates 3Cpro
Purified 3Cpro was incubated with AP, SNAP, spermine, or spermine
NONOate. (A) Analysis of the 3Cpro sulfhydryl group. Treated 3CproFigure 4. NO Inhibits 3Cpro Cleavage of Luciferase
was incubated with an excess of 5,5 dithiobis(2-nitrobenzoate)
(A) Purified 3Cpro was added to luciferase, which contains a 3Cpro (DNTB) and its absorption measured at 412 nm. n 5 4 6 SD. (B)
consensus cleavage motif, and the activity of luciferase remaining Nitrosylation of the 3Cpro active site Cys147. 3Cpro was exposed to NO
at various times was assayed using a luminometer. n 5 3 6 SD. donors or their controls, then incubated with HgCl2, and the amount(B) Increasing amounts of 3Cpro were added to luciferase for 3 hr, of nitrite released was measured by the Griess reaction. n 5 4 6 SD.
and the amount of luciferase assayed as above. n 5 3 6 SD.
(C) Luciferase was incubated alone, or in the presence of 3Cpro with
the following additions: the control compound AP, the NO donor
SNAP, SNAP and DTT, the control compound spermine (SP), the NO has no effect upon mutant C147S3Cpro activity, nor does
NO donor spermine NONOate (SP-NO), or spermine NONOate and DTT change mutant protease activity. Thus, the Cys147
DTT. n 5 3 6 SD. of the catalytic triad is critical in determining the suscep-
tibility of 3Cpro to NO.
cysteine residue. Since the active site Cys147 is the only
cysteine residue in 3Cpro, the data imply that NO nitrosy- Discussion
lates the active site cysteine residue.
The major finding of this study is that NO inhibits Cox-
sackievirus replication at least in part by nitrosylatingMutating the CVB3 Protease Active Site Cysteine
to Serine Renders the Protease the cysteine residue in the active site of a viral protease,
thereby drastically reducing the activity of this enzyme.Resistant to NO
To confirm that nitrosylation of the active site Cys147 is This protease is critical to the life cycle of Picornavi-
ruses. Nitrosylation of cysteine residues is one mecha-responsible for the inhibition of 3Cpro, we created a mu-
tant protease by PCR-directed mutagenesis, substitut- nism by which NO can directly modify a polypeptide,
and NO in theory can reduce the activity of an enzymeing a serine for the cysteine at position 147. The resultant
mutant protease, C147S3Cpro, still has catalytic activity, if its catalytic site includes a cysteine residue (Stamler
et al., 1992b, 1997; Stamler, 1994). For example, NOalthough at a level greatly reduced from wild-type prote-
ase, as others have shown (Ivanoff et al., 1986; Ham- inhibits activity of the cysteine protease caspase-3 (Kim
et al., 1997; Li et al., 1997; Mannick et al., 1997; Mohrmerle et al., 1991; Miyashita et al., 1993). The effect of
NO upon protease activity was determined by adding et al., 1997). Although proteins capable of being nitrosy-
lated at a cysteine residue contain a consensus nitrosy-NO donors and luciferase to either wild-type or mutant
protease. NO reduces wild-type 3Cpro activity, and DTT lation motif, the 3Cpro lacks this sequence (Stamler et al.,
1997). Coxsackievirus may have a selective advantage ifrestores wild-type protease activity (Figure 6). However,
Nitric Oxide Inhibition of Coxsackievirus Protease
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such as members of the Picornavirus family and the
Coronavirus family (Mannick, 1995; Reiss and Komatsu,
1998). In contrast, NO does not inhibit the replication of
some viruses that encode serine proteases, such as
alphaviruses. However, NO also inhibits the replication
of some viruses that do not encode cysteine proteases,
implying that there exist other viral targets of NO. For
example, the EBV transcription factor Zta and ribonucle-
otide reductase may be targets of NO (Mannick et al.,
1994; Melkova and Esteban, 1995). Nonetheless, to our
knowledge there are no viruses that have cysteine prote-
ases that are resistant to NO.
Cysteine proteases are also critical to the replicationFigure 6. Mutation of the 3Cpro Active Site Cys147 Renders 3Cpro Re-
sistant to NO and virulence of a variety of other micro-organisms. In-
A mutant 3Cpro with serine substituted for cysteine at amino acid hibitors of cysteine proteases block the replication of
residue 147 was purified from bacteria. Wild-type 3Cpro (1 mg/ml) Plasmodium falciparum, Plasmodium berghei, Leish-
and mutated 3Cpro (5 mg/ml) were incubated for 3 hr with luciferase mania major, Schistosoma mansoni, and Trypanosoma
and AP, SNAP, or SNAP and DTT, and the activity of luciferase
cruzi. (Bailly et al., 1992; Eakin et al., 1992; Harth et al.,assayed in a luminometer. n 5 3 6 SD, repeated twice with similar
1993; Kumar et al., 1994; Li et al., 1994; McGrath etresults.
al., 1995; Wasilewski et al., 1996; Selzer et al., 1997).
Furthermore, inhibitors of cysteine proteases also re-
its viral protease lacks a nitrosylation consensus se-
duce the virulence of Streptococcus pyogenes, Porphy-quence, decreasing cysteine reactivity to NO. The other
romonas gingivalis, Schistosoma mansoni, Naegleriaprotease of Coxsackievirus, 2Apro, is also a cysteine
fowler, and Plasmodium flaciparum. (Kapur et al., 1993a,protease, and may be a target of NO as well.
1993b; Aldape et al., 1994; Bedi and Williams, 1994;Previously, we showed that NO inhibits Coxsackie-
Gluzman et al., 1994; Musser et al., 1996; Wasilewski etvirus replication in vitro and that NO reduces both viral
al., 1996; Kuramitsu et al., 1997; Lukomski et al., 1997;RNA synthesis and viral protein synthesis (Zaragoza et
Gubba et al., 1998). (For example, the malaria parasiteal., 1997). NO inactivation of 3Cpro could explain this
uses its cysteine protease falcipain to degrade hemoglo-reduction in both viral RNA and viral protein levels, given
bin for use as a source of amino acids, and cysteinethe characteristics of the Coxsackievirus life cycle. After
protease inhibitors block the ability of the parasite toCoxsackievirus enters the cell, viral RNA is translated
infect erythrocytes and to replicate [Gluzman et al.,into a large polyprotein. The 3Cpro excises itself from the
1994; Dominguez et al., 1997].) It is striking that NOpolyprotein and cleaves the polyprotein into its compo-
inhibits the replication of all of these parasites (Mannick,nents, including 3Dpol. This RNA-dependent RNA poly-
1995; Fang, 1997; MacMicking et al., 1997; Reiss andmerase 3Dpol then replicates the viral genome. Thus,
Komatsu, 1998). NO production may thus be a general3Cpro processing acts upstream of viral RNA synthesis
mechanism by which the host defends itself againstand is necessary to generate 3Dpol. Therefore, nitrosyla-
infection by viruses and other pathogens whose life cy-tion and inactivation of 3Cpro would be expected to block
cle depends upon cysteine proteases.not only viral protein processing but also viral RNA syn-
thesis.
Although our data suggest that NO inhibits activity of
Experimental ProceduresCoxsackievirus protease 3Cpro, there are other potential
viral targets of NO as well. For example, NO could affect
Cells and Viruses
the RNA polymerase activity of 3Dpol. Although 3Dpol Coxsackievirus B3 (CVB3) (Nancy strain, generous gift of C.G.
lacks the typical molecular targets of NO, cysteine resi- Gauntt) was grown in HeLa cells and measured by the plaque assay
dues or iron in its active site, NO could affect its activity (Gauntt et al., 1979; Zaragoza et al., 1997).
To measure the effect of the NO donor SNAP upon proteolyticby other mechanisms. It is also possible that NO could
processing of CVB3 polypeptides in cells, CVB3 at an MOI of 10inactivate host proteins necessary for viral replication.
was added to HeLa cell cultures and 200 mM SNAP was added afterThe lack of effect of NO upon viral replication when NO
1 hr, and cells were harvested at various times afterward and cellis added to cells prior to infection argues against this
lysates fractionated by SDS-PAGE and analyzed by immunoblotting.
possibility (Figure 1). Nonetheless, NO can affect a vari- Guanidine HCl 3 mM, a specific inhibitor of CVB3 RNA replication,
ety of host proteins; however, the net effect of NO upon was added to all infected cells 3 hr after infection in order to inhibit
host processes either harmful or beneficial to viral repli- new viral RNA synthesis.
cation is unknown. To measure the effect of endogenously synthesized NO upon
proteolytic processing of CVB3 polypeptides in cells, CVB3 at anThe genomes of many viruses encode a polyprotein
MOI of 10 was added to HeLa cell cultures in 6-well plates, andthat after translation is cleaved into smaller polypeptides
then macrophages (that previously had been plated onto cell cultureby a viral protease. These proteases fall into several
inserts and then stimulated or not for 16 hr with LPS 10 ng/ml pluscategories based on their active site residues, including
interferon-m 50 U/ml) were added to the 6-well plates. In some wells
cysteine proteases, serine proteases, and aspartic pro- containing infected HeLa cells and activated macrophages, nitro-
teases (KraÈ usslich and Wimmer, 1988; Hellen et al., arginine-methyl-ester (NAME) was added. Cells were harvested 5
1989; Babe and Craik, 1997). NO can inhibit the replica- hr after infection and cell lysates fractionated by SDS-PAGE and
analyzed by immunoblotting.tion of other viruses that encode cysteine proteases,
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Immunoblot Analysis John H. Davis Foundation (C. J. L.), and a grant from the Bernard
Bernard Foundation (C. J. L.).Immunoblotting was performed as described previously, using an
antibody to CVB3 2C (generous gift of Christine Hohenadl) or anti-
body to GST (Pharmacia) (Zaragoza et al., 1997).
Received July 8, 1998; revised November 16, 1998.
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